GlobeNewswire Inc.··Phathom Pharmaceuticals, Inc.Phathom's VOQUEZNA Posts 104% Revenue Growth Ahead of DDW 2026 Showcase
Phathom Pharmaceuticals reports Q1 2026 revenues of $58.3M, up 104% YoY, as VOQUEZNA reaches 1.35M prescriptions. Company to present clinical data at Digestive Disease Week.
PHATrevenue growthGERD